MedTrace Logo

Efficacy and Safety of Lactoferrin in Heart Failure Patients

NCT06427200 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2024-05-24

No results posted yet for this study

Summary

This study will be conducted to determine the efficacy and safety of lactoferrin versus oral iron versus lactoferrin plus oral iron as an add on therapy in reduced ejection fraction heart failure patients with iron deficiency.

•Patients will be randomly distributed into the three groups

* All patients will be subjected to baseline data assessment
* Follow up after 12 weeks

Conditions

  • Heart Failure With Reduced Ejection Fraction

Interventions

DRUG

oral Iron

oral iron once daily during or after meals as add-on therapy for 12 weeks.

DRUG

Lactoferrin

lactoferrin twice daily before meals as add-on therapy for 12 weeks.

DRUG

lactoferrin and oral iron

lactoferrin twice daily before meals and oral iron once daily during or after meals as add-on therapy for 12 weeks.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-31
Primary Completion
2027-07-31
Completion
2027-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06427200 on ClinicalTrials.gov